(Doesn't matter if it's one box or five, call us to
verify if the special is still on-going. Prices subject to change.)
We Introduced Latisse to Modesto, CA in March 2009
Surgical Artistry, Inc is led by
Modesto Plastic Surgeon Dr.
Tammy Wu and Acupuncturist/Botox Surgeon Dr. Calvin Lee. From the makers of
BOTOX cosmetic (Allergan,
Latisse is the first and only FDA-approved eyelash growth treatment.
Date of FDA Approval of Latisse: December 24, 2008
Chemical Name of Latisse: bimatoprost ophthalmic
Bimatoprost was first approved in 2001 to lower intraocular pressure (IOP) in
patients with ocular hypertension (open-angle glaucoma). Visit our
Latisse is available at
Surgical Artistry, Modesto, CA
Latisse for Thicker Eyelashes
Now, you can grow longer, fuller, darker
It's your own eyelashes
Picture from Allergan, the makers of Latisse, Botox,
LATISSE™ (bimatoprost ophthalmic solution) 0.03% is the first treatment approved by the FDA
and currently is the only prescription treatment for inadequate or
insufficient eyelashes (Hypotrichosis), growing them longer, fuller and darker.
LATISSE™ makes lash growth possible because of its active
ingredient: bimatoprost. Although the precise mechanism of action is
not known, research suggests that the growth of eyelashes occurs by
increasing the percent of hairs in, and the duration of, the anagen
(or growth) phase. Lashes can grow longer,thicker and darker because
bimatoprost can also prolong this growth phase. Latisse is
believed to be a prostaglandin structural analog.
Prostaglandin receptors are present in the
dermal papilla and outer root sheath of the hair follicle.
Clinically proven results you can see over
time and with continued use.
LATISSE™ is easy to use, FDA approved and effective. It’s a
once-a-day treatment you apply topically to the base of your upper
eyelashes. Patients in a clinical trial saw results gradually over
time (starting at 4 weeks with full results after 16 weeks).
Latisse is an innovation backed by research.
While LATISSE™ is a new treatment in eyelash growth, it was
developed through years of research by Allergan, a pharmaceutical
leader with over 60 years of expertise in prescription eye care
risks for eye color - see discussion on Real Self webiste. Most
say that it is a minimal risk. The risk is for the active
ingredient in Latisse which is also used as an glaucoma eye-drop.
Latisse isn't designed to be used directly in the eye.